Gyre Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Gyre Therapeutics, Inc. (GYRE) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $3.14 per share as of 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2026-05-08
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $3.14.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $3.09.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $2.68.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $2.60.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2026-03-31 | $3.14 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $3.09 10-Q · filed 2026-05-08 | |
| 2025-09-30 | $2.68 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $2.60 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $2.28 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $1.75 10-K · filed 2026-03-13 | |
| 2024-09-30 | $1.74 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $1.45 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $1.46 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $1.49 10-K · filed 2025-03-17 | |
| 2023-09-30 | $1.32 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $1.32 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $1.30 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $0.75 10-K · filed 2024-03-27 | $1.42 10-K · filed 2023-03-30 |
| 2022-09-30 | $1.42 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $5.64 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $5.92 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $7.70 10-K · filed 2023-03-30 | |
| 2021-09-30 | $7.65 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $7.66 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $7.92 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $8.59 10-K · filed 2022-03-31 | |
| 2020-09-30 | $8.84 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $9.43 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $9.86 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $10.85 10-K · filed 2022-03-31 | |
| 2019-09-30 | $10.99 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $11.14 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $11.17 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $12.04 10-K · filed 2021-03-04 | |
| 2018-09-30 | $12.10 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $14.67 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $14.15 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $13.69 10-K · filed 2020-02-20 | |
| 2017-09-30 | $14.30 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $114.09 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $120.00 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $128.25 10-K · filed 2019-03-08 | |
| 2016-09-30 | $8.90 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $8.76 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $9.81 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $147.45 10-K · filed 2018-03-19 | $9.84 10-K · filed 2016-03-09 |
| 2014-12-31 | $134.40 10-K · filed 2017-03-08 | $8.93 10-K · filed 2015-03-16 |
| 2013-12-31 | $8.88 10-K · filed 2016-03-09 | $9.93 10-K · filed 2014-03-14 |
| 2012-12-31 | $8.12 10-K · filed 2016-03-09 | $10.84 10-K · filed 2013-03-15 |
| 2011-12-31 | $14.51 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |